PIAS1-mediated GSK3β SUMOylation exacerbates tauopathy and cognitive deficits in Alzheimer's disease models.

You-Lan Qiu Suo Wu Yi Zhong Di Fan Q. Tong Jing Xiong Kun Xu Gang Liu Enjie Liu Xiaoguang Li Kai Huang

Jul 2026 · Molecular Psychiatry · 1 citation · 62 references

Medicine

TL;DR

A novel PIAS1-GSK3β signaling axis in tauopathy and a cell-permeable blocking peptide designed to disrupt the PIAS1-GSK3β interaction are uncovered and provide a promising targeted therapeutic strategy for Alzheimer's disease.

DOI PubMed Semantic Scholar

View source

Similar papers

Review Aug 2026

Tau dysfunction in alzheimer’s disease: molecular and cellular mechanisms, genetic modulation, and therapeutic perspectives

Findings support a model in which tau dysfunction results from the convergence of molecular aberrations and genetic susceptibility within a pathological network involving amyloid-β, neuroinflammation, and synaptic failure.

S. Sura, S. Jagadeesan, M. A. M. Moklas et al. · Molecular Biology Reports · 0 citations

Aug 2026

Vorinostat ameliorates cognitive impairment and Tau pathology in an AAV-P301L-Tau-induced tauopathy mouse model: insights into neuroinflammation and PI3K/AKT/GSK3β signaling.

Results indicate that SAHA can improve Tau-associated pathological alterations in an AAV-P301L-Tau-induced tauopathy model, and provide additional insights into the potential influence of biological sex on HDACi-based therapeutic strategies, although the molecular mechanisms underlying these differences require further...

Zhidan Shi, Xinyi Cheng, Chu Zhang et al. · International Immunopharmaco... · 0 citations

Review Open access Aug 2026

Investigating the Mechanistic Role of piRNA Dysregulation in Amyloid-beta Toxicity and Tau Pathology in Alzheimer’s Disease Pathophysiology: Implications for Therapeutic Targets

This review synthesizes current knowledge regarding piRNA dysregulation in AD, examining mechanistic links between piRNA loss, transposable element activation, Aβ toxicity, and tau pathology while evaluating therapeutic implications.

S. Taherkhani, Zeynab Sharifiaghdam, Parnian Amani · SVOA Neurology · 0 citations

Sep 2026

Circ_0004801 promotes tau hyperphosphorylation and cognitive impairment in Alzheimer's disease through the miR-7688-5p/TTBK1 axis.

Circ_0004801 acts as an upstream regulator of TTBK1 by sequestering miR-7688-5p, thereby promoting tau hyperphosphorylation and cognitive impairment in AD and may represent a potential target for tau-directed intervention.

Qing-Qing Li, Jie Xiao, Guo-Rong Deng et al. · Journal of Alzheimer's Disea... · 0 citations

Open access Aug 2026

A conserved serotonin receptor pathway is a druggable modifier of Tau pathology, neural circuit formation and neurodegeneration

A new Drosophila tauopathy model expressing eGFP-tagged human TauWT or the disease-associated TauP301L variant in the nervous system is established and 5-HT7R signaling is identified as a conserved and druggable modifier of Tau toxicity.

Mariana I. Tsap, Valeriya V. Navrotska, J. Labus et al. · bioRxiv · 0 citations

Review Open access Aug 2026

Tau Protein Pathology and Tau-Targeted Therapeutic Strategies in Alzheimer’s Disease: Mechanisms, Clinical Evidence and Future Perspectives

Though no tau-targeted therapy has yet to demonstrate definitive clinical benefit, continued research supports tau as an important therapeutic target and contributes to the development of more effective treatments for AD.

Zhuo-Yu Wang · MedScien · 0 citations